Biogen BIIB
NASDAQ BIIB
$215.50 -3.55 (-1.62%)
At close: Sep 18, 2026 · 4:00 PM EDT

Biogen (BIIB) Income towards Parent Company (2009 - 2026)

Biogen (BIIB) posted Income towards Parent Company of $97.5 million for Q2 2026, down 69.48% on a QoQ basis from $319.5 million in Q1 2026, and down 84.64% year-over-year from $634.8 million in Q2 2025.

Analysis

Biogen (BIIB) Income towards Parent Company (2009 - 2026) Analysis & Trends

Biogen has reported Income towards Parent Company for 18 years, with the latest figure at $97.5 million in Q2 2026.

  • On a quarterly basis, Income towards Parent Company fell 84.64% year-over-year to $97.5 million in Q2 2026; TTM through Jun 2026 was $834.6 million, a 45.47% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 20.79% from the prior year.
  • Income towards Parent Company was $97.5 million for Q2 2026 at Biogen, down from $319.5 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $1.1 billion in Q3 2022, with the low at -$68.3 million in Q3 2023.
  • Average Income towards Parent Company over 5 years is $414.6 million, with a median of $388.0 million recorded in 2023.
  • The sharpest annual moves came in 2022 and 2025: Income towards Parent Company soared 1538.48% in 2022, then slumped 118.34% in 2025.
  • Over 5 years, Income towards Parent Company stood at $549.5 million in 2022, then slumped by 54.7% to $248.9 million in 2023, then climbed by 7.15% to $266.7 million in 2024, then plunged by 118.34% to -$48.9 million in 2025, then jumped by 299.39% to $97.5 million in 2026.
  • The last three Income towards Parent Company figures came in at $97.5 million (Q2 2026), $319.5 million (Q1 2026), and -$48.9 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.50 Mn
Mar 31, 2026 319.50 Mn
Dec 31, 2025 -48.90 Mn
Sep 30, 2025 466.50 Mn
Jun 30, 2025 634.80 Mn
Mar 31, 2025 240.50 Mn
Dec 31, 2024 266.70 Mn
Sep 30, 2024 388.50 Mn
Jun 30, 2024 583.60 Mn
Mar 31, 2024 393.40 Mn
Dec 31, 2023 248.90 Mn
Sep 30, 2023 -68.30 Mn
Jun 30, 2023 593.30 Mn
Mar 31, 2023 387.60 Mn
Dec 31, 2022 549.50 Mn
Sep 30, 2022 1.13 Bn
Jun 30, 2022 1.05 Bn
Mar 31, 2022 221.80 Mn
Dec 31, 2021 -38.20 Mn
Sep 30, 2021 317.00 Mn